Answers are grounded in this paper and cite their sources.
Background The effects of cycling-based exercise across Knee Injury and Osteoarthritis Outcome Score (KOOS) domains in patients with knee osteoarthritis (KOA) are uncertain. This work evaluated end-of-treatment effects on KOOS pain, activities of daily living (ADL), symptoms, quality of life (QOL), and sport/recreation domains. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, four databases were searched through 6 August 2026 (PROSPERO CRD420251267069). Eligible randomized or minimization-based trials compared cycling-based exercise with non-cycling controls. Mean differences (MDs) and 95% confidence intervals (CIs) were pooled using restricted maximum likelihood random-effects models with modified Knapp–Hartung inference. RoB 2 and GRADE were applied. Results Eight reports representing six independent trials were included; 463–538 participants contributed across outcomes. Cycling-based exercise favored KOOS pain (MD = 6.15, 95% CI: 1.34–10.96; p = 0.022; I 2 = 75.8%; low-certainty evidence), ADL (MD = 5.73, 95% CI: 2.66–8.80; p = 0.005; moderate-certainty evidence), and symptoms (MD = 3.05, 95% CI: 0.29–5.82; p = 0.036; moderate-certainty evidence). Effects for QOL (MD = 6.20, 95% CI: −2.10 to 14.49; p = 0.098; low-certainty evidence) and sport/recreation (MD = 3.73, 95% CI: −0.30 to 7.75; p = 0.062; low-certainty evidence) were not statistically clear. Pain showed substantial heterogeneity, and the pooled 95% CI included zero in two leave-one-out analyses. Sensitivity analyses were broadly consistent with the primary interpretation. Exploratory analyses showed no consistent weekly dose gradient. Conclusions Cycling-based exercise may improve KOOS pain. It likely produces a small improvement in ADL at the end of treatment and may also slightly improve symptoms. Benefits for QOL and sport/recreation remain uncertain. Cycling may be considered as an adjustable exercise option for adults with KOA, although an optimal dose or program duration was not identified. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251267069 , identifier CRD420251267069.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: